Monday, 1 June 2020

Superdisintegrants Systems Market Likely Boost The Industry Revenue And Demand Till 2023

Market Scenario:
The Global Superdisintegrants Market is anticipted to grow at an optimistic CAGR of 7.9% during the forecast period from 2018 to 2023. Disintegrants are substances which are included in drug formula to allow proper disintegration of the capsule or tablet into easily dissolvable particles. This plays a vital function in the fast absorption of medicine which increases its efficacy. Superdisintegrants are slightly modified disintegrants which offer higher efficiency than their traditional counterparts. Observed to have valued at USD 371 Mn in 2017, the global superdisintegrants market size is poised to appreciate to reach an estimated value of USD 576.2 Mn by the end of 2023.
The pharmaceutical industry is growing at breakneck speed, becoming a significant part of the healthcare sector. This is primarily due to rising populations of both geriatric patients and pediatric patients. Superdisintegrants are helpful for treatment of patients from this demographic as these tablets are easier to swallow. The growth of these demographics is expected to drive market growth. Moreover, generic drugs are in high demand as patents have begun to run out on several popular drug brands, thus opening up the pharmaceutical industry for increased entry of competition and a rise in the manufacturing of generic drugs, thus driving superdisintegrants market demand.
Emerging markets represent significant opportunity as the healthcare sectors in these regions are growing at a swift pace. Moreover, large patient pools are in these countries are expected to increase demand for fast-acting medication. Market players are likely to establish themselves in the region in an effort to leverage the opportunities available in emerging economies.
Players Covered
Prominent market participants that have been profiled in the report include Asahi Kasei Corporation, DFE Pharma, JRS Pharma, Corel Pharma Chem, Ashland Global Holdings Inc., BASF SE, Roquette Freres, DowDuPont Inc., Merck KGaA, and Avantor Performance Materials, LLC
Market Segmentation
MRFR's analysis of the various segments in the market has been performed on the basis of type, formulation, therapeutic area, and region. Types of superdisintegrants have been segmented into synthetic superdisintegrants, natural disintegrants, and others. Among these, the synthetic superdisintegrants segment has been widely used, making it the most significant market segment. However, the natural superdisintegrants segment is growing at a truly rapid pace due to the growing demand for natural ingredients.
Formulations which include superdisintegrants have been segmented into tablets and capsules. Tablets govern a majority share of the total market, while the capsules segment is expected to grow at the highest CAGR during the review period.
Therapeutic areas where superdisintegrants are used have been segmented into gastrointestinal diseases, neurological diseases, oncology, infectious diseases, inflammatory diseases, hematological diseases, and cardiovascular diseases. Among these segments, the gastrointestinal diseases segment is at the forefront of market growth due to the demand for fast acting medicine for these types of diseases. Meanwhile, the oncology segment is growing rapidly and is expected to display the highest CAGR over the forecast period.
Regional Analysis
Led by the U.S, the Americas have captured the largest share of the global superdisintegrants market. The presence of a developed healthcare sector as well as several important market players that have and continue to influence growth and contribute to the sizeable share that this regional market possesses. The region also has a high demand for drugs for many chronic diseases where superdisintegrants are required due to the prevalence of such diseases.
The Asia Pacific superdisintegrants market is likely to grow at the highest pace due to the concentration of rapidly emerging markets in the region. China, Japan, India, and several other country-level markets have a high demand for drugs for chronic diseases. The APAC regional market has several avenues for growth that are expected to open up in the coming years. The regions rapidly growing healthcare sector and the presence of a number of contract manufacturing organizations for pharmaceuticals is likely to have a positive impact on the market.
Posted by at No comments:

Gestational Trophoblastic Disease Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2023

Market Scenario:
Gestational trophoblastic disease (GTD) is a cluster of rare tumors that include abnormal growth of cells inside a woman's uterus. It arises from placental trophoblastic tissue and is characterized by β-subunit of human chorionic gonadotrophin (β HCG). The increasing prevalence of risk factors such as smoking, sexually transmitted diseases (STD), history of miscarriages, and high maternal age are expected to fuel the growth of the market during the forecast period. Rise in ectopic pregnancies is also a significant factor which causes GTD. According to the National Center for Biotechnology Information (NCBI), the risk of ectopic pregnancy is 20 times higher in women who smoke. On the other hand, high risks of recurrence and complications that may occur after the therapy and treatment procedure may hinder the growth of the market during the forecast period.
The global gestational trophoblastic disease treatment market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic partnerships to strengthen its market position. For instance, in September 2018, Novartis AG entered into a license and collaboration agreement with Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company which develops therapies for cancer and degenerative diseases in Greater China.
Competitive Landscape:
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Antares Pharma
  • Mylan N.V.
  • Novartis AG
  • BP Pharmaceuticals Laboratories Company
  • Fresenius Kabi AGAccord Healthcare, Inc.
  • Eli Lilly and Company
  • Sanofi
  • Bayer AG
  • Amgen Inc.
  • Merck
Segmentation:The global gestational trophoblastic disease market has been segmented into type, treatment, and end user.
The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.
The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole. The market, based on hydatidiform mole is expected to hold the largest share as it is the most common form of the gestational trophoblastic disease,  whereas choriocarcinoma is projected to be the fastest-growing market as the incidence rate of this form is increasing steadily according to a journal published by National Center for Biotechnology Information.
The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy.
The market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.
The market, by end user, has been segmented into hospital and clinics, diagnostic centers, and others.
The market has been segmented regionally into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gestational trophoblastic disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gestational trophoblastic disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The gestational trophoblastic disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gestational trophoblastic disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is projected to dominate the global gestational trophoblastic disease market owing to an increased awareness about the disease and favorable reimbursement scenario. Also, the rise in a number of marketing approvals, as well as product approvals in the field of oncology drive the market growth.
Europe is expected to hold the second largest position in the global gestational trophoblastic disease market. The market growth in this region is attributed to the availability of funds for research and an increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
On the other hand, the Middle East and Africa has the least share of the market. This is due to the stringent government regulations and lack of technical expertise in the treatment of the disease.
Posted by at No comments:

Male Breast Cancer Market Shares Analysis, Key Development Strategies And Forecasts Till 2023

Market Scenario:
Although breast cancer is common in women, even men suffer from the same. Men also have breast tissues and cancer starts when these tissues start to grow out of control. The breast ducts and glands present in men are not functional, but cancer in these areas can spread when cancer cells enter the blood or lymph system and are carried in the whole body. Men who have suffered from cancer before and undergone radiation therapy are at a high risk of suffering from male breast cancer.
The rising geriatric population and an increasingly obese population resulting in high levels of estrogen in males are expected to drive the growth of the market during the forecast period. According to an article published by the National Cancer Institute in April 2018, most of the men who suffer from breast cancer are 60 to 70 years old. Additionally, the rising healthcare expenditure is likely to boost the market growth. On the other hand, lack of knowledge of the disease and high cost of treatment may hinder the growth of the market during the forecast period.
The global male breast cancer treatment market is expected to grow slowly at a CAGR of ~ 3.6% during the forecast period from 2018 to 2023. Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.
Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.
Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.
Key players
Achieve Life Sciences, Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, and Bayer AG are some of the key players in the global male breast cancer market.
Segmentation
The global male breast cancer market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.
The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.
By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.
The market, by treatment, has been segmented into, local treatments and systemic treatments.
By treatment, local treatments are further segment into, surgery and radiation therapy.
Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.
By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.
Hormone therapy is further segmented into, using drugs and orchiectomy (castration).
Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.
Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.
The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global male breast cancer market owing to the changing lifestyle and rising prevalence of breast cancer. According to an article published by, the American Cancer Society in April 2018, the lifetime risk of getting breast cancer in men is approximately 1 in 833. Europe is expected to hold the second largest position in the global male breast cancer market. The market growth in this region is attributed to the growing prevalence of rare cancers, the availability of funds for research, and increasing healthcare expenditure. According to the Cancer Research UK, 371 new cases of male breast cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising awareness regarding early symptoms of cancer and government support for healthcare facilities. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cases of cancer in China in 2015.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to growing government initiatives for the healthcare sector.
Posted by at No comments:

Pulmonary Atresia Diagnostics and Treatment Market Professional Overview 2019-2023 With Major Vendors Size, Shares And Worldwide Demand

Pulmonary atresia is the type of inherited heart defect that a baby is born with. It arises when the pulmonary valve normally located between the right ventricle and the pulmonary artery doesn’t form properly. The valve should have three leaflets which allow the blood to flow forward into the pulmonary artery but prevent it from flowing backward into the right ventricle. In the case of congenital pulmonary atresia patients, the valve either malfunctions or does not form at all. The tissue formed in the place of pulmonary valve does not allow the blood flow into the pulmonary artery. This flaw develops in the first eight weeks of pregnancy and disturbs the flow of blood from the right ventricle to the pulmonary artery leading to the lungs. It can be recognized in a prenatal ultrasound.
The Global Pulmonary Atresia Diagnostics and Treatment Market Growth is expected to register a significant CAGR during the forecast period (2018–2023).
The most common symptoms are blue or gray-toned skin, troubled breathing, weakness, sleepiness, and others. Factors such as technological advancements, increasing awareness, lifestyle changes are the major driving factors for the growth of the market. However, unspecified regulatory issues, infection risks connected with surgical procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restrains for the market include the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the pulmonary atresia diagnostics and treatment market negatively. 
Key Players
Some of the key players in the global pulmonary atresia diagnostics and treatment market are Kyowa Pharma Chemical Co. Ltd, AZAD partners, Abbott Laboratories, Dickinson and Company, Becton, C. R. Bard, Inc., B. Braun Melsungen AG, Medtronic plc., Teleflex Incorporated, JOHNSON & JOHNSON, Cook Group Incorporated, and Boston Scientific Corporation.
Segmentation
The global pulmonary atresia diagnostics and treatment market has been segmented on the basis of type, diagnosis, treatment and end users.
On the basis of treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization is segmented into radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery is segmented into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant.
On the basis of type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect.
On the basis of diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European pulmonary atresia diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The pulmonary atresia diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pulmonary atresia diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to the Centers for Disease Control and Prevention, congenital heart defects are a foremost cause of birth defect associated with infant illness and deaths. The deaths often occur when the infant is less than 28 days old and hence diagnosis of the defect is utmost important.
In the pulmonary atresia diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into medical devices manufacturing. According to the Centers for Disease Control and Prevention, about 40,000 births are affected by congenital heart defects in the US every year.
Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.
The market in the Middle East & Africa is expected to account for the smallest share of the global pulmonary atresia diagnostics and treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.
Posted by at No comments:

Endovascular Aneurysm Repair Devices Market Report By Global Industry Trends And Forecast The Upcoming Opportunities And Demand Till 2023

Market Scenario

Global endovascular aneurysm repair devices market is likely to grow significantly over the forecast period. It is estimated that the global endovascular aneurysm repair devices market is expected to record a CAGR ~ 6.4 % during the forecast period of 2018 to 2023. The weakening and bulging of the aorta is called aortic aneurysm. The bulging can cause a leak that spills blood into the body. It can direct the blood flow away from the organs and tissues, causing severe complications, such as kidney damage, heart attacks, stroke, and even death. Thus, endovascular repair can be done by placing a stent-graft in an aneurysm through a small hole in the blood vessels in the groin area.
Numerous factors such as reduced recovery times, low-cost hospitalization charges, and technological advancements in repair devices are expected to drive the growth of the market. For instance, in March 2017, Terumo Corporation completed the acquisition of Bolton Medical, Inc. with the acquired company being a leading innovator in thoracic and abdominal stent graft systems, Terumo Corporation aimed to strengthen its growth in vascular graft segment.
However, stringent government regulation, the preferable alternative of open surgery and various complications such as endoleaks and infections may hamper the market growth during the assessment period.
Segmentation
The global endovascular aneurysm repair devices market has been segmented into indication, site, anatomy, and products.
The market, on the basis of indication, has been segmented into the abdominal aortic aneurysm, thoracic aortic aneurysm and others.
The market, based on thoracic aortic aneurysm, has been further segmented into ascending aortic aneurysm, descending aortic aneurysm, thoracoabdominal aortic aneurysm, and thoracic arch aortic aneurysm.
The market, on the basis of the site, has been segmented into infrarenal and pararenal.
The market, based on pararenal site, has been sub-segmented into juxtarenal and suprarenal.
The market, on the basis of anatomy, has been segmented into traditional and complex.
The market, on the basis of products, has been segmented into percutaneous EVAR, fenestrated EVAR, aortic stents and TAA grafts, and others.
Key players
Cardiatis SA, Cardinal Health, Cook Medical LLC, Endologix, INC., Jotec GmbH, Medtronic plc, Terumo Corporation, W. L. Gore & Associates, Inc., BiFlow Medical Ltd, Boston Scientific Corporation, Braile Biomédica, Endoluminal Sciences Pty Ltd, Endospan Ltd., Getinge AB, and Lemaitre Vascular Inc. are some of the key players in the global endovascular aneurysm repair devices market.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The endovascular aneurysm repair devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European endovascular aneurysm repair devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The endovascular aneurysm repair devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The endovascular aneurysm repair devices market in the Middle East and Africa has been segmented into the Middle East, and Africa.
The Americas is expected to dominate the global endovascular aneurysm repair devices market owing to increasing geriatric population, and well-developed healthcare sector. With the increase in the geriatric population, the prevalence of aneurysms is also expected to rise. The Centers for Disease Control and Prevention (CDC) ranks abdominal aortic aneurysm as one of the top 15 causes of mortality in the United States, but only for those between 85 and 89 years. According to the Centers for Disease Control and Prevention, aortic aneurysms were the primary cause of 9,863 deaths in 2014 in the US.
Europe is expected to hold the second largest position in the global endovascular aneurysm repair devices market. The market growth in this region is attributed to the growing prevalence of aneurysms, availability of funds for research, and favorable reimbursement scenario.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.
Posted by at No comments:

Worldwide Fibrocystic Breasts Diagnostics and Treatment Market Witness A Remarkable Growth Projected By 2023

More than half of women experience fibrocystic breast changes at some point in their lives. According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.
The fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition in which the breasts feel lumpy. The breast lumps are due to fibrocystic changes. These lumps are formed due to the collection of fibrous tissue at an area of the breast. The ligaments and scar tissues are made up of fibrous tissue. the changes in breast tissue due to the fluctuating hormone levels made by the ovaries results in the occurrence of fibrocystic breasts. The changes seem to be troublesome and result in breast swelling and painful breast lumps. It mainly affects women between their 30s and 50s and lingers through their perimenopause and menopause. Presence of fibrocystic breast disease increases the risk of breast cancer.
The global fibrocystic breasts diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).
Increase in incidences of breast cancer; especially among women above the age of 35 during menopause (are more susceptible to breast cancer), and growth in awareness regarding breast cancer screening programs drive the market growth. Additionally, the emergence of technologically advanced and minimally invasive breast biopsy devices is expected to provide lucrative opportunities in the untapped market.  However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively. 
Key Players
Some of the key players in the global fibrocystic breast diagnostics and treatment market are Argon Medical Devices, Boston Scientific, CareFusion Corporation (Acquired by Becton, Dickinson and Company), C. R. Bard, Inc, Cook Medical, Devicor Medical Products Inc., Gallini Medical Devices, Hologic, Inc., INRAD, Inc., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, Allergan plc.
Regional Analysis
In the fibrocystic breast diagnostics and treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into cancer diagnostic. Whereas the market share in Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increasing government initiatives and rising healthcare expenditure.
The European market is expected to hold the second largest market share. The market growth in this region can be attributed to increasing amount of alcohol consumption by women, changes in estrogen levels due to increase in intake of birth control pills and increasing use of hormone replacement therapy (HRT) are boosting the European market.
The market in the Middle East & Africa is expected to account for the smallest share of the global fibrocystic breast diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Segmentation
The global fibrocystic breasts diagnostics and treatment market has been segmented into type and end users.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The treatment is segmented into medications, fine-needle aspiration, surgical excision, oral contraceptives. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, rehab centers, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European fibrocystic breasts diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The fibrocystic breasts diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fibrocystic breasts diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Posted by at No comments:

World Malaria Diagnostics Market Top Key Players Shares, Revenue, Analysis And Forecasts To 2023

The Global Malaria Diagnostics Market Expected to Garner a CAGR of 4.63% During the assessment period between 2018 and 2023. It is reported in a study released by Market Research Future (MRFR), that the market is positively influenced by a number of factors.
Malaria is a serious life-threatening disease caused by a parasite, transmitted by the bite of infected anopheles mosquitoes. Infected mosquitoes transport the Plasmodium parasite. When the infected mosquito bites you, the parasite is released into your bloodstream. Once the human body becomes the host for the parasite it travels to the liver and matures. After some days, the mature parasite enters the bloodstream and starts to infect red blood cells (RBC). Humans suffering from malaria frequently experience fever, headache, weakness, vomiting
A major factor influencing this growth is the increasing advancements in technology related to diagnostic tools and the proliferating demand for such treatments in malaria-endemic countries. Other factors driving the market growth are rising support from the government in terms of investment funds and an increase in the collaboration between the research centers and the industry. Malaria diagnostic tests play a significant role in identifying malarial cases, which thereby boosts the growth of the overall malaria diagnostic market trends and size.
However, the lack of precise monitoring standards at developing nations, acts as a major factor constraining the market. The lack of awareness among emerging nations and work regulatory framework is of particular concern for both manufacturers and healthcare providers.
Key Players
Some of the key players in the global malaria diagnostics market are Access Bio. Inc., Abbott Laboratories, Premier Medical Corporation Pvt. Ltd, Sysmex Partec GmbH, bioMérieux, Beckman Coulter Inc., Siemens Healthineers, Leica Microsystems GmbH, Nikon Corporation, Olympus Corporation, and Bio-Rad Laboratories Inc.
Segmentation
The global malaria diagnostics market has been segmented on the basis of technology and end-user.
On the basis of technology, the market has been classified as rapid diagnostic tests, microscopy, and molecular diagnostic tests. The molecular diagnostics tests are segmented into polymerase chain reaction (PCR) and real-time polymerase chain reaction (RT-PCR).
On the basis of end-users, the market has been classified as hospitals, clinics, community healthcare, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European malaria diagnostics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The malaria diagnostics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The malaria diagnostics market in the Middle East and Africa has been segmented into the Middle East and Africa. 
Regional Market Summary
In the malaria diagnostics market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures. In 2016, global governments of malaria-endemic countries have invested USD 2.7 billion in malaria control and elimination efforts. The US was the largest contributor by providing USD 1 billion for the eradication of malaria.
The European market is expected to hold the least share due to the growing number of malaria-free countries in the region.
The market in the Middle East and Africa is expected to account for the smallest share of the global malaria diagnostics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities. Sub-Saharan Africa remains to bring an excessively high share of the global malaria burden on the Middle Eastern and African market. the region was home to 90% of malaria incidences and 92% of malaria deaths in 2015
The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism. The Asia-Pacific remains to be the second largest burden of malaria globally with 22 malaria-endemic countries accounting for roughly 28 million cases and 45,000 deaths every year. The WHO figures say that in the Asia-Pacific region, Myanmar, Pakistan, India, and Indonesia carry the highest malaria burden accounting for 89% of all malaria cases in the region.
Posted by at No comments:
Subscribe to: Posts (Atom)